Black men with PCa face persistent disparities in SDoH, resulting in reduced prostate-specific antigen (PSA) screening, limited access to staging imaging, non-guideline-concordant care, a higher burden of comorbidities, and restricted access to curative treatment (3, 10–13). The gene discussed is KLK3; the disease is posterior cortical atrophy.